141 related articles for article (PubMed ID: 25059491)
1. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
[TBL] [Abstract][Full Text] [Related]
2. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and pathological analyses of bevacizumab-induced renal impairment in four patients].
Zhao J; Li H; Zhang L; Zhong W; Li LY; Wen YB; Wang MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Apr; 34(2):153-8. PubMed ID: 22776601
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
11. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
13. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.
Iwasa S; Nakajima TE; Nagashima K; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2013 Jan; 33(1):309-16. PubMed ID: 23267162
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
15. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab safety in patients with central nervous system metastases.
Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP
Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762
[TBL] [Abstract][Full Text] [Related]
18. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
[TBL] [Abstract][Full Text] [Related]
19. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
Launay-Vacher V; Janus N; Beuzeboc P; Daniel C; Ray-Coquard I; Selle F; Rey JB; Jouannaud C; Spano JP; Thery JC; Morere JF; Goldwasser F; Mir O; Oudard S; Scotté F; Dorent R; Ludwig L; Deray G; Gligorov J
Bull Cancer; 2015 Nov; 102(11):906-14. PubMed ID: 26603517
[TBL] [Abstract][Full Text] [Related]
20. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
